Brief: Coya Therapeutics Receives Clinical Trial Application Acceptance From Health Canada
23/12/2025 13:20
Dec 23 (Reuters) - Coya Therapeutics Inc COYA.O: COYA THERAPEUTICS RECEIVES CLINICAL TRIAL APPLICATION (CTA) ACCEPTANCE FROM HEALTH CANADA TO PROCEED WITH THE COYA 302 ALSTARS TRIAL FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) COYA THERAPEUTICS INC - ALSTARS TRIAL UNDERWAY IN US AND CANADA Source text: ID:nBw9n9x0Pa Further company coverage: COYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)